📰 Dror Bashan News
Page 3 - Dror Bashan News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Dror Bashan. Real-time updates on events, politics, business and more.
May 5, 2023
/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...
May 5, 2023
Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2023 Financial Business Results Conference Call.
May 4, 2023
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization...
May 4, 2023
Protalix BioTherapeutics Reports First Quarter 2023 Financial and Business Results - read this article along with other careers information, tips and advice on BioSpace
March 21, 2023
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
March 1, 2023
Operator: Good morning ladies and gentlemen and welcome to the Protalix full year 2022 earnings call. As a reminder, this conference is being recorded.
February 27, 2023
A PEGylated enzyme replacement therapy for Fabry disease has received a positive opinion from the EMA's human medicines committee.
February 24, 2023
/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...
January 3, 2023
/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...
December 29, 2022
Treatments for blood cancer and rare diseases are the target markets, but investors are well aware of the challenges that await after approval is received.